Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record.

BMS‐204352: A Potassium Channel Opener Developed for the Treatment of Stroke

Open access
Jensen, Bo Skaaning·2002·CNS Drug Reviews

Abstract

During ischemic stroke, a fatal biochemical cascade that results in neuronal hyperexcitability is initiated when neurons at risk are exposed to excessive excitatory amino acids and pathologically high levels of intracellular calcium (Ca 2+). Therefore, neuroprotectants including NMDA‐antagonists and blockers of voltage‐gated Ca 2+channels have been proposed as novel strategies for stroke treatment. Since potassium channels are key players in the control of neuronal excitability, and activation of neuronal potassium channels decrease excitability and neurotransmitter release, a novel approach for targeting acute ischemic stroke has been to develop openers of neuronal potassium channels. Bristol‐Myers Squibb is developing BMS‐204352, a fluoro‐oxindole potassium channel opener, as a potential neuroprotectant for the treatment of acute ischemic stroke. BMS‐203252 is a potent and effective opener of two important subtypes of neuronal potassium channels, the calcium‐activated, big‐conductance potassium channels (K Ca channels) and voltage‐dependent, non‐inactivating potassium channels known as KCNQ channels. BMS‐204352 (0.3 mg/kg, i.v.) significantly reduced cortical infarct volume in a model of permanent occlusion of the middle cerebral artery (MCA) in spontaneous hypertensive rats (SHR), as compared to vehicle when administered 2 h post‐occlusion. At doses from 1 μg/kg to 1 mg/kg i.v., BMS‐204352 produced a significant reduction in cortical infarct volume in normotensive Wistar rats. In healthy humans, single and multiple i.v. doses of BMS‐204352 (0.001 to 0.2 mg/kg) were safe, well‐tolerated and without psychomotor function effects. Multiple doses of BMS‐204352 (0.1–2 mg/kg i.v.) administered within 48 h after stroke onset were well tolerated in patients in Phase II studies, designed to evaluate safety, tolerability and pharmacokinetics. No clinically significant differences in organ toxicity or adverse effects were found, and total clearance and volume of distribution were independent of dose. BMS‐204352 failed to show superior efficacy in acute stroke patients compared to placebo in a Phase III study that included 1978 patients at 200 centers worldwide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1527-3458.2002.tb00233.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 223

Metadata

Authors
Jensen, B. S.
Venue
CNS Drug Reviews
Publisher
Wiley
Published
2002-12
Volume
8
Issue
4
Pages
353-360
ISSN
  • 1080-563X (ISSN-L)
  • 1527-3458
OpenAlex
W2069232604
Cited by
223
References
0
FWCI
0.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BMS‐204352: A Potassium Channel Opener Developed for the Treatment of Stroke. https://app.cochat.ai/papers/10.1111/j.1527-3458.2002.tb00233.x
The paper
Jensen, B. S. (2002). BMS‐204352: A Potassium Channel Opener Developed for the Treatment of Stroke. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2002.tb00233.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.